首页 > 最新文献

Leukemia research最新文献

英文 中文
Genomic profiling reveals molecular heterogeneity in patients with Richter transformation (RT) and chronic lymphocytic leukemia (CLL) 基因组分析揭示里希特转化(RT)和慢性淋巴细胞白血病(CLL)患者的分子异质性
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-11 DOI: 10.1016/j.leukres.2025.108133
Shulan Tian , Hanyin Wang , Sameer A. Parikh , Yuanhang Liu , Helen Jin-Lee , Erik Jessen , Eric W. Klee , Yucai Wang , Fan Leng , Min Shi , Cinthya Zepeda-Mendoza , Rong He , Saad J. Kenderian , Linda B. Baughn , Daniel L. Van Dyke , Paul J. Hampel , Neil E. Kay , Esteban Braggio , Susan L. Slager , Huihuang Yan , Wei Ding
Richter transformation (RT) represents the development of an aggressive lymphoma in chronic lymphocytic leukemia (CLL). Patients with RT and relapsed CLL have poor outcomes. Yet, the molecular differences between the two entities have not been fully explored. In this pilot study, we conducted RNA-seq and targeted panel sequencing of nodal tissues from 12 patients, including seven with RT and five with CLL. Analysis of RNA-seq data revealed two major clusters, with five RT in cluster C1 and the remaining two RT and all five CLL in C2. Within C2, one of the CLL ultimately developed RT; it showed more similarity to the two RT than to the other CLL in expression profile, suggesting the presence of expression signature for RT prior to the clinical diagnosis. In addition, differentially expressed genes, the majority of which showed higher expression in C1 relative to C2, were enriched in pathways known to be important for CLL pathogenesis or transformation. Deconvolution of the bulk RNA-seq data revealed major differences in cellular composition between the two clusters, notably tumor B cells, macrophages M1, and CD8 + T cells. Furthermore, by targeted sequencing, we identified 51 genes that carried recurrent copy number alterations (CNAs) preferentially occurring in either cluster. Over 80 % of these CNAs occurred in C2, mainly gains of 17q12q25 in CLL. Patients in C1 had shorter overall survival (median 11 months) compared to those in C2 (median 36 months). Together, our findings highlight noticeable differences in transcriptomic and genomic alterations between CLL versus RT.
里希特转化(RT)代表慢性淋巴细胞白血病(CLL)侵袭性淋巴瘤的发展。放疗和复发的CLL患者预后较差。然而,这两种实体之间的分子差异尚未得到充分探讨。在这项初步研究中,我们对12名患者的淋巴结组织进行了RNA-seq和靶向小组测序,其中包括7名RT患者和5名CLL患者。RNA-seq数据分析显示两个主要集群,C1集群中有5个RT, C2集群中其余2个RT和所有5个CLL。在C2内部,一个CLL最终开发了RT;在表达谱上,它与两种RT比与其他CLL更相似,表明在临床诊断之前存在RT的表达特征。此外,差异表达的基因,其中大多数在C1中相对于C2表达更高,在已知的CLL发病或转化的重要途径中富集。大量RNA-seq数据的反褶积揭示了两个集群之间细胞组成的主要差异,特别是肿瘤B细胞,巨噬细胞M1和CD8 + T细胞。此外,通过靶向测序,我们确定了51个基因携带复发性拷贝数改变(CNAs),优先发生在两个集群中。超过80% %的CNAs发生在C2,主要是CLL中17q12q25的增加。C1组患者的总生存期(中位11个月)短于C2组(中位36个月)。总之,我们的研究结果突出了CLL与RT之间转录组学和基因组改变的显著差异。
{"title":"Genomic profiling reveals molecular heterogeneity in patients with Richter transformation (RT) and chronic lymphocytic leukemia (CLL)","authors":"Shulan Tian ,&nbsp;Hanyin Wang ,&nbsp;Sameer A. Parikh ,&nbsp;Yuanhang Liu ,&nbsp;Helen Jin-Lee ,&nbsp;Erik Jessen ,&nbsp;Eric W. Klee ,&nbsp;Yucai Wang ,&nbsp;Fan Leng ,&nbsp;Min Shi ,&nbsp;Cinthya Zepeda-Mendoza ,&nbsp;Rong He ,&nbsp;Saad J. Kenderian ,&nbsp;Linda B. Baughn ,&nbsp;Daniel L. Van Dyke ,&nbsp;Paul J. Hampel ,&nbsp;Neil E. Kay ,&nbsp;Esteban Braggio ,&nbsp;Susan L. Slager ,&nbsp;Huihuang Yan ,&nbsp;Wei Ding","doi":"10.1016/j.leukres.2025.108133","DOIUrl":"10.1016/j.leukres.2025.108133","url":null,"abstract":"<div><div>Richter transformation (RT) represents the development of an aggressive lymphoma in chronic lymphocytic leukemia (CLL). Patients with RT and relapsed CLL have poor outcomes. Yet, the molecular differences between the two entities have not been fully explored. In this pilot study, we conducted RNA-seq and targeted panel sequencing of nodal tissues from 12 patients, including seven with RT and five with CLL. Analysis of RNA-seq data revealed two major clusters, with five RT in cluster C1 and the remaining two RT and all five CLL in C2. Within C2, one of the CLL ultimately developed RT; it showed more similarity to the two RT than to the other CLL in expression profile, suggesting the presence of expression signature for RT prior to the clinical diagnosis. In addition, differentially expressed genes, the majority of which showed higher expression in C1 relative to C2, were enriched in pathways known to be important for CLL pathogenesis or transformation. Deconvolution of the bulk RNA-seq data revealed major differences in cellular composition between the two clusters, notably tumor B cells, macrophages M1, and CD8 + T cells. Furthermore, by targeted sequencing, we identified 51 genes that carried recurrent copy number alterations (CNAs) preferentially occurring in either cluster. Over 80 % of these CNAs occurred in C2, mainly gains of 17q12q25 in CLL. Patients in C1 had shorter overall survival (median 11 months) compared to those in C2 (median 36 months). Together, our findings highlight noticeable differences in transcriptomic and genomic alterations between CLL versus RT.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"160 ","pages":"Article 108133"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145537567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia Isavuconazole为急性髓系白血病患者提供有效且可耐受的抗真菌预防。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-28 DOI: 10.1016/j.leukres.2025.108144
Cameron J. Hunter , Andrew Chou , Heidi Roeder , William Eighmy , Jan Philipp Bewersdorf , Lourdes Mendez , Maximilian Stahl , Nikolai A. Podoltsev , Amer M. Zeidan , Rory M. Shallis
Voriconazole has been a standard antifungal prophylactic (AFP) agent for patients with acute myeloid leukemia (AML) during neutropenia. However, its use is complicated by side-effects including transaminase elevations, visual disturbances, and significant drug-drug interactions (DDIs). Isavuconazole is an AFP agent with a more attractive side-effect profile. In a retrospective analysis we compared rates of complications necessitating AFP withdrawal between patients with AML who initially started on isavuconazole (n = 63) or voriconazole (n = 215), and of invasive fungal infection (IFI) and median overall survival (OS) between patients who used only isavuconazole (n = 41) or voriconazole (n = 90). Voriconazole was associated with higher rates of AFP discontinuation due to transaminase elevations (p = 0.019), visual disturbances (p = 0.002), or DDIs (p = 0.002), while isavuconazole was more frequently discontinued due to coverage denial/high cost (p < 0.0001). Rates/classification of IFI, breakthrough IFI (bIFI) and IFI-free survival (IFI-FS) were comparable between azoles in both analyses. Isavuconazole is an effective AFP agent with a superior side-effect profile and should thus be considered as a promising AFP option for patients with AML.
伏立康唑一直是中性粒细胞减少期间急性髓性白血病(AML)患者的标准抗真菌预防(AFP)药物。然而,它的使用是复杂的副作用,包括转氨酶升高,视力障碍,和显著的药物-药物相互作用(ddi)。Isavuconazole是一种AFP药物,副作用更明显。在一项回顾性分析中,我们比较了最初开始使用isavuconazole (n = 63)或voriconazole (n = 215)的AML患者需要停用AFP的并发症发生率,以及仅使用isavuconazole (n = 41)或voriconazole (n = 90)患者的侵袭性真菌感染(IFI)和中位总生存期(OS)。由于转氨酶升高(p = 0.019)、视力障碍(p = 0.002)或ddi (p = 0.002),Voriconazole与较高的AFP停药率相关,而isavuconazole则因拒绝覆盖/高成本而更频繁地停药(p
{"title":"Isavuconazole provides effective and tolerable antifungal prophylaxis for patients with acute myeloid leukemia","authors":"Cameron J. Hunter ,&nbsp;Andrew Chou ,&nbsp;Heidi Roeder ,&nbsp;William Eighmy ,&nbsp;Jan Philipp Bewersdorf ,&nbsp;Lourdes Mendez ,&nbsp;Maximilian Stahl ,&nbsp;Nikolai A. Podoltsev ,&nbsp;Amer M. Zeidan ,&nbsp;Rory M. Shallis","doi":"10.1016/j.leukres.2025.108144","DOIUrl":"10.1016/j.leukres.2025.108144","url":null,"abstract":"<div><div>Voriconazole has been a standard antifungal prophylactic (AFP) agent for patients with acute myeloid leukemia (AML) during neutropenia. However, its use is complicated by side-effects including transaminase elevations, visual disturbances, and significant drug-drug interactions (DDIs). Isavuconazole is an AFP agent with a more attractive side-effect profile. In a retrospective analysis we compared rates of complications necessitating AFP withdrawal between patients with AML who initially started on isavuconazole (n = 63) or voriconazole (n = 215), and of invasive fungal infection (IFI) and median overall survival (OS) between patients who used only isavuconazole (n = 41) or voriconazole (n = 90). Voriconazole was associated with higher rates of AFP discontinuation due to transaminase elevations (p = 0.019), visual disturbances (p = 0.002), or DDIs (p = 0.002), while isavuconazole was more frequently discontinued due to coverage denial/high cost (p &lt; 0.0001). Rates/classification of IFI, breakthrough IFI (bIFI) and IFI-free survival (IFI-FS) were comparable between azoles in both analyses. Isavuconazole is an effective AFP agent with a superior side-effect profile and should thus be considered as a promising AFP option for patients with AML.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"160 ","pages":"Article 108144"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145715027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories 急性髓性白血病融合基因和PCR检测的突变靶点的实验室间交叉验证:PETHEMA中心实验室的表现。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-19 DOI: 10.1016/j.leukres.2025.108149
Margarida Coucelo , Claudia Sargas , Rosa Ayala , María J. Larráyoz , María Carmen Chillón , Elena Soria , Cristina Bilbao , Esther Prados de la Torre , Maria Luis Amorim , Alberto Mirales , Antonia Cionfrini , Ana T. Simões , Ana C. Oliveira , Rebeca Rodríguez-Veiga , Pilar Lloret-Madrid , Yolanda Mendizábal , Carmen Botella , Teresa Bernal , Juan Bergua , Lorenzo Algarra , Eva Barragán
The rapid and accurate laboratory identification of targetable therapeutic genes, together with the implementation of measurable residual disease (MRD) based decision is essential for optimal clinical management in acute myeloid leukemia (AML). The PETHEMA (Programa Español de Tratamientos en Hematología) cooperative group comprises nine laboratories that perform centralized molecular studies by conventional PCR and Real-time quantitative PCR (RT-qPCR) for AML patients. With the aim to validate laboratories performances, we conducted three rounds of interlaboratory cross validation (ICV) for the quantification of CBFB::MYH11, RUNX1::RUNX1T1 and NPM1 and one round to determine the mutational status of NPM1, FLT3 (ITD and TKD2) IDH1 and IDH2. For RT-qPCR a total of 19 samples were tested and only 3 (15.8 %) failed to achieve 100 % concordance, corresponding to samples with low target gene mean ratios (ICV1-S4, ICV2-S1, ICV2-S6). For mutation detection in a total of 227 returned results, concordance rate ranged from 95 % to 100 %. FLT3-ITD and NPM1 mutation detection had 100 % concordant results. One false negative was reported for IDH2- R140 mutation and 4 false positives were detected: 2 FLT3-TKD2 and 2 IDH1-R132, likely reflecting differences in assay sensitivity. Overall, the results were highly satisfactory, particularly regarding MRD assessment, and highlighted key points for improvement, especially in baseline detection of FLT3-TKD2 and IDH1 mutations. This study represents the first collaborative initiative to evaluate performance of AML molecular targets within a laboratory network and underscores the importance of regular exercises to monitor performance, identify and resolve technical or interpretive discrepancies to ultimately ensure accurate clinical decision-making.
快速准确的实验室鉴定靶向治疗基因,以及基于可测量残留病(MRD)的决策的实施,对于急性髓性白血病(AML)的最佳临床管理至关重要。PETHEMA (Programa Español de Tratamientos en Hematología)合作小组由9个实验室组成,通过传统PCR和实时定量PCR (RT-qPCR)对AML患者进行集中的分子研究。为了验证实验室性能,我们进行了三轮实验室间交叉验证(ICV)来量化CBFB::MYH11、RUNX1::RUNX1T1和NPM1,并进行了一轮实验室间交叉验证(ICV)来确定NPM1、FLT3 (ITD和TKD2) IDH1和IDH2的突变状态。RT-qPCR共检测了19个样本,只有3个(15.8 %)未能达到100 %的一致性,对应于低靶基因平均比率的样本(ICV1-S4, ICV2-S1, ICV2-S6)。对于227个返回结果的突变检测,一致性率从95 %到100 %不等。FLT3-ITD与NPM1突变检测结果吻合度为100% %。报告了1例IDH2- R140突变假阴性和4例假阳性:2例FLT3-TKD2和2例IDH1-R132,可能反映了测定敏感性的差异。总体而言,结果非常令人满意,特别是在MRD评估方面,并强调了改进的关键点,特别是在FLT3-TKD2和IDH1突变的基线检测方面。该研究是首次在实验室网络中评估AML分子靶点表现的合作倡议,并强调了定期锻炼以监测表现、识别和解决技术或解释差异的重要性,最终确保准确的临床决策。
{"title":"Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories","authors":"Margarida Coucelo ,&nbsp;Claudia Sargas ,&nbsp;Rosa Ayala ,&nbsp;María J. Larráyoz ,&nbsp;María Carmen Chillón ,&nbsp;Elena Soria ,&nbsp;Cristina Bilbao ,&nbsp;Esther Prados de la Torre ,&nbsp;Maria Luis Amorim ,&nbsp;Alberto Mirales ,&nbsp;Antonia Cionfrini ,&nbsp;Ana T. Simões ,&nbsp;Ana C. Oliveira ,&nbsp;Rebeca Rodríguez-Veiga ,&nbsp;Pilar Lloret-Madrid ,&nbsp;Yolanda Mendizábal ,&nbsp;Carmen Botella ,&nbsp;Teresa Bernal ,&nbsp;Juan Bergua ,&nbsp;Lorenzo Algarra ,&nbsp;Eva Barragán","doi":"10.1016/j.leukres.2025.108149","DOIUrl":"10.1016/j.leukres.2025.108149","url":null,"abstract":"<div><div>The rapid and accurate laboratory identification of targetable therapeutic genes, together with the implementation of measurable residual disease (MRD) based decision is essential for optimal clinical management in acute myeloid leukemia (AML). The PETHEMA (Programa Español de Tratamientos en Hematología) cooperative group comprises nine laboratories that perform centralized molecular studies by conventional PCR and Real-time quantitative PCR (RT-qPCR) for AML patients. With the aim to validate laboratories performances, we conducted three rounds of interlaboratory cross validation (ICV) for the quantification of <em>CBFB::MYH11, RUNX1::RUNX1T1</em> and <em>NPM1</em> and one round to determine the mutational status of <em>NPM1</em>, <em>FLT3</em> (ITD and TKD2) <em>IDH1</em> and <em>IDH2</em>. For RT-qPCR a total of 19 samples were tested and only 3 (15.8 %) failed to achieve 100 % concordance, corresponding to samples with low target gene mean ratios (ICV1-S4, ICV2-S1, ICV2-S6). For mutation detection in a total of 227 returned results, concordance rate ranged from 95 % to 100 %. <em>FLT3</em>-ITD and <em>NPM1</em> mutation detection had 100 % concordant results. One false negative was reported for <em>IDH2</em>- R140 mutation and 4 false positives were detected: 2 <em>FLT3</em>-TKD2 and 2 <em>IDH1</em>-R132, likely reflecting differences in assay sensitivity. Overall, the results were highly satisfactory, particularly regarding MRD assessment, and highlighted key points for improvement, especially in baseline detection of <em>FLT3</em>-TKD2 and <em>IDH1</em> mutations. This study represents the first collaborative initiative to evaluate performance of AML molecular targets within a laboratory network and underscores the importance of regular exercises to monitor performance, identify and resolve technical or interpretive discrepancies to ultimately ensure accurate clinical decision-making.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"160 ","pages":"Article 108149"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy or CAR-T cells for relapsed/refractory acute lymphoblastic leukemia: A multicenter phase ii trial PD-1/PD-L1抑制剂联合化疗或CAR-T细胞治疗复发/难治性急性淋巴细胞白血病的疗效和安全性:一项多中心ii期试验
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-12 DOI: 10.1016/j.leukres.2025.108148
Min Zou, Bolin Wan, Jing Hu

Introduction

Relapsed or refractory acute lymphoblastic leukemia (R/R ALL) remains a major therapeutic challenge with poor long-term survival outcomes. Although checkpoint inhibitors targeting PD-1/PD-L1 have shown efficacy in other hematologic malignancies, their role in ALL has not been fully defined. Combination strategies integrating PD-1/PD-L1 blockade with chemotherapy or CAR-T cells may enhance anti-leukemic responses and overcome immune resistance.

Methods

In this multicenter, open-label Phase II trial, 168 patients with R/R ALL were randomized to receive either FLAG chemotherapy plus nivolumab (Group A), CD19-directed CAR-T cells plus atezolizumab (Group B), or FLAG alone (Control). The primary endpoint was progression-free survival (PFS); secondary outcomes included overall survival (OS), MRD negativity, and safety. Immune profiling assessed biomarkers like PD-L1, TIM-3, CD25 + , and cytokines.

Results

MRD negativity rates were significantly higher in experimental arms compared to control (Group A: 19.5 %; Group B: 27.8 %; Control: 3 %; p < 0.001). Median PFS was 7.7 months in Group A, 11.7 months in Group B, and 4.1 months in the control group (p < 0.001). Median OS was 10.75, 13.5, and 5.65 months, respectively (p < 0.001). Higher baseline PD-L1 expression was independently associated with improved survival (HR 0.90 per 10 % increase; p = 0.002). The addition of checkpoint inhibitors did not significantly increase severe toxicities, and infection rates were lower in experimental groups compared to control. The swimmer plot analysis demonstrated prolonged remission in MRD-negative patients.

Conclusion

Adding PD-1 or PD-L1 blockade to either chemotherapy or CAR-T therapy improved clinical outcomes without excess toxicity in R/R ALL.
复发或难治性急性淋巴细胞白血病(R/R ALL)仍然是一个主要的治疗挑战,长期生存结果不佳。虽然靶向PD-1/PD-L1的检查点抑制剂在其他血液系统恶性肿瘤中显示出疗效,但它们在ALL中的作用尚未完全确定。将PD-1/PD-L1阻断与化疗或CAR-T细胞结合的联合策略可能增强抗白血病反应并克服免疫抵抗。方法在这项多中心、开放标签的II期临床试验中,168例R/R ALL患者随机接受FLAG化疗+纳武单抗(A组)、cd19靶向CAR-T细胞+阿特唑单抗(B组)或FLAG单独(对照组)。主要终点是无进展生存期(PFS);次要结局包括总生存期(OS)、MRD阴性和安全性。免疫谱分析评估生物标志物,如PD-L1, TIM-3, CD25 + 和细胞因子。结果实验组smrd阴性率显著高于对照组(A组:19.5 %;B组:27.8 %;对照组:3 %;p <; 0.001)。A组的中位PFS为7.7个月,B组为11.7个月,对照组为4.1个月(p <; 0.001)。中位OS分别为10.75、13.5和5.65个月(p <; 0.001)。较高的基线PD-L1表达与生存率的提高独立相关(HR 0.90 / 10 %增加;p = 0.002)。添加检查点抑制剂并没有显著增加严重毒性,实验组的感染率比对照组低。游泳者图分析显示mrd阴性患者缓解时间延长。结论在化疗或CAR-T治疗中加入PD-1或PD-L1阻断剂可改善R/R ALL的临床结果,且无过量毒性。
{"title":"Efficacy and safety of PD-1/PD-L1 inhibitors in combination with chemotherapy or CAR-T cells for relapsed/refractory acute lymphoblastic leukemia: A multicenter phase ii trial","authors":"Min Zou,&nbsp;Bolin Wan,&nbsp;Jing Hu","doi":"10.1016/j.leukres.2025.108148","DOIUrl":"10.1016/j.leukres.2025.108148","url":null,"abstract":"<div><h3>Introduction</h3><div>Relapsed or refractory acute lymphoblastic leukemia (R/R ALL) remains a major therapeutic challenge with poor long-term survival outcomes. Although checkpoint inhibitors targeting PD-1/PD-L1 have shown efficacy in other hematologic malignancies, their role in ALL has not been fully defined. Combination strategies integrating PD-1/PD-L1 blockade with chemotherapy or CAR-T cells may enhance anti-leukemic responses and overcome immune resistance.</div></div><div><h3>Methods</h3><div>In this multicenter, open-label Phase II trial, 168 patients with R/R ALL were randomized to receive either FLAG chemotherapy plus nivolumab (Group A), CD19-directed CAR-T cells plus atezolizumab (Group B), or FLAG alone (Control). The primary endpoint was progression-free survival (PFS); secondary outcomes included overall survival (OS), MRD negativity, and safety. Immune profiling assessed biomarkers like PD-L1, TIM-3, CD25 + , and cytokines.</div></div><div><h3>Results</h3><div>MRD negativity rates were significantly higher in experimental arms compared to control (Group A: 19.5 %; Group B: 27.8 %; Control: 3 %; p &lt; 0.001). Median PFS was 7.7 months in Group A, 11.7 months in Group B, and 4.1 months in the control group (p &lt; 0.001). Median OS was 10.75, 13.5, and 5.65 months, respectively (p &lt; 0.001). Higher baseline PD-L1 expression was independently associated with improved survival (HR 0.90 per 10 % increase; p = 0.002). The addition of checkpoint inhibitors did not significantly increase severe toxicities, and infection rates were lower in experimental groups compared to control. The swimmer plot analysis demonstrated prolonged remission in MRD-negative patients.</div></div><div><h3>Conclusion</h3><div>Adding PD-1 or PD-L1 blockade to either chemotherapy or CAR-T therapy improved clinical outcomes without excess toxicity in R/R ALL.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"160 ","pages":"Article 108148"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NGS-based quantitative typing to identify HLA loss relapse after allogeneic stem cell transplantation 基于ngs的定量分型鉴定同种异体干细胞移植后HLA丢失复发。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-10 DOI: 10.1016/j.leukres.2025.108135
Kairi Kojo , Daichi Sadato , Takashi Toya , Keisuke Oboki , Chizuko Hirama, Yasumasa Nishito, Chika Kato, Hiroaki Shimizu, Kyoko Haraguchi, Hironori Harada, Yoshiki Okuyama, Yuka Harada, Noriko Doki, Yuho Najima
{"title":"NGS-based quantitative typing to identify HLA loss relapse after allogeneic stem cell transplantation","authors":"Kairi Kojo ,&nbsp;Daichi Sadato ,&nbsp;Takashi Toya ,&nbsp;Keisuke Oboki ,&nbsp;Chizuko Hirama,&nbsp;Yasumasa Nishito,&nbsp;Chika Kato,&nbsp;Hiroaki Shimizu,&nbsp;Kyoko Haraguchi,&nbsp;Hironori Harada,&nbsp;Yoshiki Okuyama,&nbsp;Yuka Harada,&nbsp;Noriko Doki,&nbsp;Yuho Najima","doi":"10.1016/j.leukres.2025.108135","DOIUrl":"10.1016/j.leukres.2025.108135","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"160 ","pages":"Article 108135"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145564391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Double IGHV rearrangements in a Latin American cohort of chronic lymphocytic leukemia patients 拉丁美洲慢性淋巴细胞白血病患者的双IGHV重排。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-19 DOI: 10.1016/j.leukres.2025.108151
Carmen Stanganelli, Juana Cabrera, Andrea Bender, Evangelina Agriello, Davi Coe Torres, Gerson Moura Ferreira, Maria Paula Mota dos Santos, Eliana Saul Furquim Werneck Abdelhay, Irma Slavutsky
{"title":"Double IGHV rearrangements in a Latin American cohort of chronic lymphocytic leukemia patients","authors":"Carmen Stanganelli,&nbsp;Juana Cabrera,&nbsp;Andrea Bender,&nbsp;Evangelina Agriello,&nbsp;Davi Coe Torres,&nbsp;Gerson Moura Ferreira,&nbsp;Maria Paula Mota dos Santos,&nbsp;Eliana Saul Furquim Werneck Abdelhay,&nbsp;Irma Slavutsky","doi":"10.1016/j.leukres.2025.108151","DOIUrl":"10.1016/j.leukres.2025.108151","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"160 ","pages":"Article 108151"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IGF2BP3 promotes acute myeloid leukemia cell progression by regulating Semaphorin 4D stability in an m6A-dependent manner IGF2BP3通过m6a依赖的方式调节Semaphorin 4D的稳定性,从而促进急性髓系白血病细胞的进展。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-10-10 DOI: 10.1016/j.leukres.2025.108119
Juan Li , Shulan Shi , Kefu Zhu , Linyang Zhe , Tianle Lu , Quanzhen Deng , Qingfang Li , Qiuling Hou , Tilong Huang , Qiangming Sun , Ming Yu , Hongchao Jiang

Background

Our previous findings indicate Semaphorin 4D (Sema4D) as a potential pediatric leukemia biomarker, promoting leukemogenesis via PI3K/AKT and ERK pathways, but its upstream regulatory mechanisms remain unclear. This study was conducted to explore the potential regulatory relationship between Insulin growth factor 2 mRNA binding protein 3 (IGF2BP3) and Sema4D in acute myeloid leukemia (AML).

Methods

The expression levels of Sema4D and IGF2BP3 were analyzed in PBMCs from 41 newly diagnosed patients with pediatric acute myeloid leukemia (AML) and 35 healthy pediatric donors who presented no history of leukemia using western blotting and qRT-PCR. IGF2BP3 overexpression and knockdown models were established in Kasumi-1 and HL-60 cells via lentiviral infection. Cell proliferation, apoptosis, and cell cycle distribution were assessed using CCK-8 and flow cytometry. The stability of Sema4D mRNA and m6A methylation levels were evaluated via mRNA stability assay and qPCR.

Results

This study discovered that Sema4D and IGF2BP3 were overexpressed in the peripheral blood mononuclear cells (PBMCs) of AML patients, and their expression levels were positively correlated. IGF2BP3 overexpression enhanced cell proliferation and cell cycle progression, and inhibited apoptosis in AML cells, while knockdown had the opposite effect. Mechanistic exploration revealed that IGF2BP3 enhances the stability of Sema4D mRNA through m6A-dependent mechanisms.

Conclusion

In this study, we demonstrate that the IGF2BP3/Sema4D axis is a crucial regulator in AML development, driving cell proliferation and survival through post-transcriptional regulation of Sema4D by IGF2BP3 in an m6A-dependent manner. Our findings highlight the potential of targeting this axis as a therapeutic strategy for AML treatment.
背景:我们之前的研究结果表明,信号蛋白4D (Sema4D)是一种潜在的儿科白血病生物标志物,通过PI3K/AKT和ERK途径促进白血病的发生,但其上游调控机制尚不清楚。本研究旨在探讨胰岛素生长因子2 mRNA结合蛋白3 (IGF2BP3)与Sema4D在急性髓性白血病(AML)中的潜在调控关系。方法:应用western blotting和qRT-PCR分析41例小儿急性髓性白血病(AML)新诊断患者和35例无白血病病史的健康儿童供者外周血中Sema4D和IGF2BP3的表达水平。通过慢病毒感染在Kasumi-1和HL-60细胞中建立IGF2BP3过表达和低表达模型。采用CCK-8和流式细胞术评估细胞增殖、凋亡和细胞周期分布。通过mRNA稳定性测定和qPCR评估Sema4D mRNA和m6A甲基化水平的稳定性。结果:本研究发现,Sema4D和IGF2BP3在AML患者外周血单个核细胞(PBMCs)中过表达,且表达水平呈正相关。IGF2BP3过表达增强AML细胞增殖和细胞周期进程,抑制细胞凋亡,而敲低则相反。机制探索表明,IGF2BP3通过m6a依赖性机制增强Sema4D mRNA的稳定性。结论:在本研究中,我们证明了IGF2BP3/Sema4D轴在AML发展中是一个重要的调节因子,通过IGF2BP3以m6a依赖的方式转录后调节Sema4D,驱动细胞增殖和存活。我们的发现强调了靶向这一轴作为AML治疗策略的潜力。
{"title":"IGF2BP3 promotes acute myeloid leukemia cell progression by regulating Semaphorin 4D stability in an m6A-dependent manner","authors":"Juan Li ,&nbsp;Shulan Shi ,&nbsp;Kefu Zhu ,&nbsp;Linyang Zhe ,&nbsp;Tianle Lu ,&nbsp;Quanzhen Deng ,&nbsp;Qingfang Li ,&nbsp;Qiuling Hou ,&nbsp;Tilong Huang ,&nbsp;Qiangming Sun ,&nbsp;Ming Yu ,&nbsp;Hongchao Jiang","doi":"10.1016/j.leukres.2025.108119","DOIUrl":"10.1016/j.leukres.2025.108119","url":null,"abstract":"<div><h3>Background</h3><div>Our previous findings indicate Semaphorin 4D (Sema4D) as a potential pediatric leukemia biomarker, promoting leukemogenesis via PI3K/AKT and ERK pathways, but its upstream regulatory mechanisms remain unclear. This study was conducted to explore the potential regulatory relationship between Insulin growth factor 2 mRNA binding protein 3 (IGF2BP3) and Sema4D in acute myeloid leukemia (AML).</div></div><div><h3>Methods</h3><div>The expression levels of Sema4D and IGF2BP3 were analyzed in PBMCs from 41 newly diagnosed patients with pediatric acute myeloid leukemia (AML) and 35 healthy pediatric donors who presented no history of leukemia using western blotting and qRT-PCR. IGF2BP3 overexpression and knockdown models were established in Kasumi-1 and HL-60 cells via lentiviral infection. Cell proliferation, apoptosis, and cell cycle distribution were assessed using CCK-8 and flow cytometry. The stability of Sema4D mRNA and m6A methylation levels were evaluated via mRNA stability assay and qPCR.</div></div><div><h3>Results</h3><div>This study discovered that Sema4D and IGF2BP3 were overexpressed in the peripheral blood mononuclear cells (PBMCs) of AML patients, and their expression levels were positively correlated. IGF2BP3 overexpression enhanced cell proliferation and cell cycle progression, and inhibited apoptosis in AML cells, while knockdown had the opposite effect. Mechanistic exploration revealed that IGF2BP3 enhances the stability of Sema4D mRNA through m6A-dependent mechanisms.</div></div><div><h3>Conclusion</h3><div>In this study, we demonstrate that the IGF2BP3/Sema4D axis is a crucial regulator in AML development, driving cell proliferation and survival through post-transcriptional regulation of Sema4D by IGF2BP3 in an m6A-dependent manner. Our findings highlight the potential of targeting this axis as a therapeutic strategy for AML treatment.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"159 ","pages":"Article 108119"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High JAK2V617F allele burden in low-risk PV: an additional recommendation to start “early” cytoreduction? Results from a multicentric study 低风险PV患者JAK2V617F等位基因负担高:“早期”细胞减少的额外建议?来自多中心研究的结果。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-10-22 DOI: 10.1016/j.leukres.2025.108123
Luca Tosoni, Sara Di Giusto, Gianluca Morelli, Melissa Bergnach, Chiara Callegari, Rossella Stella, Francesco Zaja, Antonia Schwab, Albert Wölfler, Eleonora Toffoletti, Daniela Damiani, Renato Fanin, Mario Tiribelli
{"title":"High JAK2V617F allele burden in low-risk PV: an additional recommendation to start “early” cytoreduction? Results from a multicentric study","authors":"Luca Tosoni,&nbsp;Sara Di Giusto,&nbsp;Gianluca Morelli,&nbsp;Melissa Bergnach,&nbsp;Chiara Callegari,&nbsp;Rossella Stella,&nbsp;Francesco Zaja,&nbsp;Antonia Schwab,&nbsp;Albert Wölfler,&nbsp;Eleonora Toffoletti,&nbsp;Daniela Damiani,&nbsp;Renato Fanin,&nbsp;Mario Tiribelli","doi":"10.1016/j.leukres.2025.108123","DOIUrl":"10.1016/j.leukres.2025.108123","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"159 ","pages":"Article 108123"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145409507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of interim bone marrow assessments in acute myeloid leukemia – A systematic review and meta-analysis 中期骨髓评估在急性髓性白血病中的作用——一项系统回顾和荟萃分析。
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-10-12 DOI: 10.1016/j.leukres.2025.108121
Yuanli Lei , Zhiting Tang , Jessica A. Reese , Omer Jamy , Mohamad Khawandanah , Manu Pandey , Muhammad Faisal , Adam Asch , Zimu Gong

Background

The current standard of care for acute myeloid leukemia (AML) patients undergoing intensive induction chemotherapy includes an interim bone marrow biopsy around day 14 (D14BM), and reinduction for patients with more than 5 % residual blasts on D14BM (Positive D14BM). However, this approach has become increasingly controversial. This systematic review and meta-analysis assess the sensitivity, specificity, and predictive value of D14BM in patients treated with one cycle of induction chemotherapy and evaluate the efficacy of reinduction versus observation in patients with Positive D14BM.

Methods

A systematic literature search was conducted using PubMed, Embase, Web of Science, and Cochrane databases. A bivariate model was used for pooled sensitivity and specificity. The positive predictive value was estimated based on pooled mean sensitivity, specificity, and historical refractory leukemia prevalence. Risk ratios (RR) for complete remission (CR) were meta-analyzed to compare reinduction versus observation in Positive D14BM patients.

Result

Among 1044 identified articles, 12 met inclusion criteria. Ten studies (1683 patients) evaluated the predictive value of D14BM, with a sensitivity of 49.7 % (proportion of refractory cases correctly identified by Positive D14BM) and specificity of 86.2 %. The estimated positive predictive value was 38.9 %, assuming a 15 % prevalence of true refractory leukemia. Eleven studies (832 patients) evaluated efficacy of reinduction, with a pooled RR of 1.00 (61 % vs. 60 %, 95 % CI: 0.76–1.31) for CR.

Conclusion

Positive D14BM has limited predictive power for refractory leukemia. Reinduction based on Positive D14BM does not improve CR rates compared to observation alone only and may expose patients to undue toxicity.
背景:目前接受强化诱导化疗的急性髓性白血病(AML)患者的护理标准包括在第14天左右(D14BM)进行中期骨髓活检,并对D14BM上残余细胞超过 % (D14BM阳性)的患者进行再诱导。然而,这种方法已经变得越来越有争议。本系统综述和荟萃分析评估了D14BM在接受一个周期诱导化疗的患者中的敏感性、特异性和预测价值,并评估了D14BM阳性患者再诱导与观察的疗效。方法:采用PubMed、Embase、Web of Science、Cochrane等数据库进行系统文献检索。双变量模型用于合并敏感性和特异性。阳性预测值是根据汇总的平均敏感性、特异性和难治性白血病的历史患病率来估计的。对完全缓解(CR)的风险比(RR)进行荟萃分析,比较D14BM阳性患者的再诱导和观察。结果:1044篇文献中,有12篇符合纳入标准。10项研究(1683例患者)评估了D14BM的预测价值,其敏感性为49.7 %(阳性D14BM正确识别的难治性病例比例),特异性为86.2 %。估计阳性预测值为38.9 %,假设真正难治性白血病的患病率为15 %。11项研究(832例患者)评估了再诱导对cr的疗效,合并RR为1.00(61 %对60 %,95 % CI: 0.76-1.31)。结论:D14BM阳性对难治性白血病的预测能力有限。与单独观察相比,基于阳性D14BM的再诱导不能提高CR率,并可能使患者暴露于过度的毒性。
{"title":"The role of interim bone marrow assessments in acute myeloid leukemia – A systematic review and meta-analysis","authors":"Yuanli Lei ,&nbsp;Zhiting Tang ,&nbsp;Jessica A. Reese ,&nbsp;Omer Jamy ,&nbsp;Mohamad Khawandanah ,&nbsp;Manu Pandey ,&nbsp;Muhammad Faisal ,&nbsp;Adam Asch ,&nbsp;Zimu Gong","doi":"10.1016/j.leukres.2025.108121","DOIUrl":"10.1016/j.leukres.2025.108121","url":null,"abstract":"<div><h3>Background</h3><div>The current standard of care for acute myeloid leukemia (AML) patients undergoing intensive induction chemotherapy includes an interim bone marrow biopsy around day 14 (D14BM), and reinduction for patients with more than 5 % residual blasts on D14BM (Positive D14BM). However, this approach has become increasingly controversial. This systematic review and meta-analysis assess the sensitivity, specificity, and predictive value of D14BM in patients treated with one cycle of induction chemotherapy and evaluate the efficacy of reinduction versus observation in patients with Positive D14BM.</div></div><div><h3>Methods</h3><div>A systematic literature search was conducted using PubMed, Embase, Web of Science, and Cochrane databases. A bivariate model was used for pooled sensitivity and specificity. The positive predictive value was estimated based on pooled mean sensitivity, specificity, and historical refractory leukemia prevalence. Risk ratios (RR) for complete remission (CR) were meta-analyzed to compare reinduction versus observation in Positive D14BM patients.</div></div><div><h3>Result</h3><div>Among 1044 identified articles, 12 met inclusion criteria. Ten studies (1683 patients) evaluated the predictive value of D14BM, with a sensitivity of 49.7 % (proportion of refractory cases correctly identified by Positive D14BM) and specificity of 86.2 %. The estimated positive predictive value was 38.9 %, assuming a 15 % prevalence of true refractory leukemia. Eleven studies (832 patients) evaluated efficacy of reinduction, with a pooled RR of 1.00 (61 % vs. 60 %, 95 % CI: 0.76–1.31) for CR.</div></div><div><h3>Conclusion</h3><div>Positive D14BM has limited predictive power for refractory leukemia. Reinduction based on Positive D14BM does not improve CR rates compared to observation alone only and may expose patients to undue toxicity.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"159 ","pages":"Article 108121"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145318432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world treatment patterns and clinical outcomes of patients with treatment-naïve and relapsed/refractory diffuse large B-cell lymphoma in the United States 美国treatment-naïve和复发/难治性弥漫性大b细胞淋巴瘤患者的现实世界治疗模式和临床结果
IF 2.2 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-12-01 Epub Date: 2025-10-14 DOI: 10.1016/j.leukres.2025.108117
Jennifer K. Lue , Priyanka J. Bobbili , Mahek Garg , Christopher W. Yee , Katherine E. Ryland , Sonia Gupta , Daisy Liu , Monika Raut , Mei Sheng Duh

Background

With the evolving treatment landscape and growing therapeutic options, it is essential to understand the treatments currently used in real-world clinical practice and the associated outcomes among patients with DLBCL to identify potential unmet treatment needs.

Patients and Methods

This retrospective longitudinal cohort study examined treatment patterns and outcomes for diffuse large B-cell lymphoma (DLBCL) patients using the COTA electronic health records database from 2016 to 2023. The study population included 3569 patients, treated in community oncology settings, who received first-line (1L) therapy.

Results

Nineteen percent of patients relapsed after 1L chemoimmunotherapy (primarily R-CHOP). The most common second-line treatments included rituximab-based regimens and autologous stem cell transplant (ASCT). Antibody-drug conjugates (ADCs) and CAR T-cell therapy were administered in third-line or later. Median progression-free survival (PFS) and overall survival (OS) decreased with each line. Relapsed/refractory real-world DLBCL patients experienced poor outcomes (24-month OS of 41.7 %). Patients receiving ASCT or CAR T-cell therapy had better OS than those who did not receive cellular therapies, with 24-month OS of 78 %, 54 %, and 31 %, respectively.

Conclusion

This study highlights the need for improved treatment options and increased access to novel therapies, emphasizing gaps in community oncology settings.
随着治疗领域的发展和治疗选择的增加,了解目前在现实世界的临床实践中使用的治疗方法以及DLBCL患者的相关结果对于识别潜在的未满足的治疗需求至关重要。患者和方法本回顾性纵向队列研究使用COTA电子健康记录数据库,检查2016年至2023年弥漫性大b细胞淋巴瘤(DLBCL)患者的治疗模式和结果。研究人群包括3569名在社区肿瘤学机构接受一线(1L)治疗的患者。结果1L化疗免疫治疗(以R-CHOP为主)后复发的患者占19%。最常见的二线治疗包括基于利妥昔单抗的方案和自体干细胞移植(ASCT)。抗体-药物偶联物(adc)和CAR - t细胞治疗在三线或后期进行。中位无进展生存期(PFS)和总生存期(OS)随着每条线而下降。现实世界中复发/难治性DLBCL患者的预后较差(24个月OS为41.7 %)。接受ASCT或CAR - t细胞治疗的患者比未接受细胞治疗的患者有更好的OS, 24个月的OS分别为78 %,54 %和31 %。结论:该研究强调了改善治疗方案和增加新疗法可及性的必要性,强调了社区肿瘤环境中的差距。
{"title":"Real-world treatment patterns and clinical outcomes of patients with treatment-naïve and relapsed/refractory diffuse large B-cell lymphoma in the United States","authors":"Jennifer K. Lue ,&nbsp;Priyanka J. Bobbili ,&nbsp;Mahek Garg ,&nbsp;Christopher W. Yee ,&nbsp;Katherine E. Ryland ,&nbsp;Sonia Gupta ,&nbsp;Daisy Liu ,&nbsp;Monika Raut ,&nbsp;Mei Sheng Duh","doi":"10.1016/j.leukres.2025.108117","DOIUrl":"10.1016/j.leukres.2025.108117","url":null,"abstract":"<div><h3>Background</h3><div>With the evolving treatment landscape and growing therapeutic options, it is essential to understand the treatments currently used in real-world clinical practice and the associated outcomes among patients with DLBCL to identify potential unmet treatment needs.</div></div><div><h3>Patients and Methods</h3><div>This retrospective longitudinal cohort study examined treatment patterns and outcomes for diffuse large B-cell lymphoma (DLBCL) patients using the COTA electronic health records database from 2016 to 2023. The study population included 3569 patients, treated in community oncology settings, who received first-line (1L) therapy.</div></div><div><h3>Results</h3><div>Nineteen percent of patients relapsed after 1L chemoimmunotherapy (primarily R-CHOP). The most common second-line treatments included rituximab-based regimens and autologous stem cell transplant (ASCT). Antibody-drug conjugates (ADCs) and CAR T-cell therapy were administered in third-line or later. Median progression-free survival (PFS) and overall survival (OS) decreased with each line. Relapsed/refractory real-world DLBCL patients experienced poor outcomes (24-month OS of 41.7 %). Patients receiving ASCT or CAR T-cell therapy had better OS than those who did not receive cellular therapies, with 24-month OS of 78 %, 54 %, and 31 %, respectively.</div></div><div><h3>Conclusion</h3><div>This study highlights the need for improved treatment options and increased access to novel therapies, emphasizing gaps in community oncology settings.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"159 ","pages":"Article 108117"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145517199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Leukemia research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1